Increasing scientific attention is focused on the gut-brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective-like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving chemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long-lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical evidence supporting a role for the intestinal microbiome in mediating behavioral comorbidities through peripheral immune activation in patients with cancer who are receiving chemotherapy. In addition, evidence suggesting that targeted modification of the intestinal microbiome during cancer treatment could ameliorate associated behavioral comorbidities is reviewed.
INTRODUCTION
Patients with cancer often receive chemotherapy, which targets cellular division mechanisms to impair cancer cell proliferation. Most chemotherapies lack the specificity to solely target cancer cells and, as a consequence, result in negative side effects throughout the body, including behavioral and gastrointestinal (GI)-related comorbidities. Therefore, as cancer survival rates continue to increase, 1 understanding the pathophysiology underlying these comorbidities will inform treatment options, thereby improving many lives.
Although the ability of the central nervous system (CNS) to affect GI function has a long history in physiology and medicine, the ability for intestinal microbiota (the natural community of bacteria, archaea, fungi, other single-celled eukaryotes, and viruses populating the GI tract) to influence CNS function and behavior is relatively novel. 2 Altered composition of the GI microbiota has been observed in CNS diseases such as autism, Parkinson disease, schizophrenia, and affective disorders.
in some domains, including executive function, learning and memory, visuospatial skills, attention, language, and concentration. 4, 10 Symptoms of fatigue increase during chemotherapy treatment, ranging from 28% to 90%, 5 and approximately one-third of patients with cancer report sleep disturbances (inability to fall/stay asleep, daytime dysfunction, and reduced sleep quality), which are exacerbated by chemotherapy treatments. 6 Subjective and objective behavioral symptoms may be influenced by factors outside of chemotherapy, such as tumor location, tumor stage, and patient demographics. 11, 12 For example, symptoms of fatigue and sleep disturbances may precede and be exacerbated by chemotherapy. 6, 12 Because of the treatment heterogeneity of cancer populations in clinical studies, there often is not enough statistical power to delineate the specific effects of most chemotherapeutic drugs on behavior. However, taxane-based chemotherapies in particular are associated with increased severity and duration of psychological symptoms after cancer treatment. 13 Although these behavioral symptoms may be most severe during treatment, they can last well beyond 5 years 14 and are associated with poor quality of life. 9 In addition, these comorbidities decrease the efficiency of completing simple or work-related tasks, reduce compliance with treatments, and ultimately increase mortality; 9 therefore, novel strategies are needed to reduce them.
Chemotherapy, Behavior, and the Brain in Rodent Models
Mice that receive treatment with chemotherapeutic agents (eg, taxanes, antimetabolites, alkylating agents) mirror behaviors hypothesized to be homologous to the anxiety, depression, 15, 16 and cognitive impairments observed in patients with cancer. 17, 18 Most rodent studies report increases in these negative behaviors, although the duration and magnitude of behavioral changes vary. 19 The effects of specific chemotherapeutic drugs on cognition and, to a lesser extent, affective-like behaviors in rodents were previously summarized. 19 Fewer studies have used rodent models to measure fatigue and sleep disturbances after chemotherapy. Treatment with a combination of alkylating and antimetabolite chemotherapies, as well as taxanes, chronically decreases both motivated (wheel running) and passive (horizontal movement) activity in mice. 20, 21 In another study, chemotherapy treatment acutely increased sleep during the dark phase, when mice are most active; however, these sleep bouts were fragmented and of low quality. 22 Although different chemotherapeutic agents, including those that supposedly do not cross the blood-brain barrier, impair various aspects of cell proliferation, they induce similar changes in behavior. 19 These behavioral parallels to patients with cancer observed in animal models allow researchers to systematically investigate the underlying physiological changes within the CNS after chemotherapy. Decreases in neurogenesis and general brain cell proliferation are reported after treatment with nearly all chemotherapeutic drugs. 18, 19 In addition, some drugs (alkaloids, alkylating agents, and taxanes) alter neurotransmission and cause oxidative stress in the brain, resulting in cellular dysfunction within the CNS. 23 Finally, numerous chemotherapies (alkaloids, taxanes, antimetabolites, and topoisomerase inhibitors) increase markers of inflammation within the CNS. 18, 19 For example, treatment with an alkylating chemotherapy agent activates astrocytes and microglia (the resident innate immune cells of the CNS) in a mouse model of chemotherapy-associated neuropathy. 24 Furthermore, expression of proinflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor a (TNFa), increases acutely in the CNS after chemotherapy. 25 However, not all studies report increases in microgliosis and local cytokine production, likely because of differences in the markers and chemotherapeutic drugs used and in the durations between treatment and analyses. 26 Although behavioral deficits may be caused by changes in several neurophysiological mechanisms simultaneously, for the purpose of this review, we focus on neuroinflammation as the most relevant to the gut-immunebrain axis in the context of chemotherapy.
Chemotherapy and the GI Tract in Patients With Cancer
In addition to CNS symptoms, patients with cancer who are receiving various chemotherapeutic agents experience debilitating GI side effects (diarrhea, nausea, abdominal cramping, and anorexia), 27 which are described as worse than those of cancer. Much like behavioral comorbidities, GI symptoms lead to delays in and poor adherence to cancer treatments, extreme hospital costs, and occasionally death. 27 These chemotherapy-induced GI symptoms are attributed to disruption of the natural intestinal microbiota as well as inflammation and ulceration of the intestinal mucosal cell lining (mucositis). 28 The GI tract is host to a complex community of symbiotic microorganisms, which increases in density from proximal to distal regions. These microbes help to maintain the intestinal epithelial barrier, regulate host immunity and metabolism, and modulate brain Review Article function. 2 Few studies have investigated the effects of chemotherapy on fecal microbial composition, and they are limited by low sample sizes as well as heterogeneous tumor types and chemotherapeutics. Consequently, the conclusions remain broad: acute chemotherapy reduces bacterial diversity, which is marked by decreased Lactobacillus, Enterococcus, and Bifidobacterium but increased Escherichia and Staphylococcus. [29] [30] [31] [32] Conflicting effects on Bacteroides are reported. Notably, a drastic decrease in known butyrate-producing genera, Faecalibacterium and Roseburia, was observed in one study. 29 Butyrate is an anti-inflammatory agent of microbial origin, as discussed below (see Immune Pathways From the GI Tract). In addition to receiving chemotherapy, patients with cancer may receive radiation therapy and additional drugs (eg, antibiotics) to treat the side effects of cancer treatment and reduce the risk of infection. These additional treatments surely play a role in further altering intestinal microbial composition. 33 Chemotherapy-induced alterations in fecal bacterial structure are associated with the development of mucositis. 28 Indeed, up to 80% of chemotherapy-treated patients are diagnosed with mucositis, which is the number one dose-limiting side effect of chemotherapeutic agents. 34 Chemotherapy also profoundly affects the intestinal barrier, which functions to keep resident bacteria from triggering an innate immune response. [35] [36] [37] Disturbances in the mucus layer, tight junctions, and overall tissue integrity result in the translocation of bacterial products (eg, lipopolysaccharide) leading to endotoxemia 35 or of whole bacteria (leading to bacteremia) 37 and general inflammatory responses. Although alterations in fecal microbiota after chemotherapy have been linked to the development of mucositis as well as cancer-related cachexia, 28, 35 the extent to which these alterations are associated with behavioral outcomes has yet to be reported.
Chemotherapy and the GI Tract in Rodent Models
The composition of the GI microbiome in rodents differs from that of humans; however, rodent models of chemotherapy can be useful for understanding the associated intestinal inflammation. For example, similar to that which occurs in humans with cancer, chemotherapy in mice decreases bacterial diversity and intestinal barrier function. 38, 39 In mice, the most typically abundant Bacteroides spp. are decreased, whereas low-abundance Bacteroides spp. are increased 1000-fold (up to 8% relative abundance), 39 which may explain the aforementioned conflicting Bacteroides results in chemotherapy-treated patients. Shifts in bacterial community structure are likely a multifactorial effect of individual species' susceptibility to chemotherapeutics as well as their ability to directly metabolize them. Indeed, culture-dependent analyses have revealed that the majority of retrievable bacterial colonies from the small and large intestine are directly resistant to treatments with an antimetabolite chemotherapy. 40 With respect to the ability for specific species to metabolize chemotherapeutic drugs, chemotherapy increases b-glucuronidase-producing bacteria, which can reactivate glucuronidated (biologically inactivated) chemotherapeutics in the GI tract, contributing to intestinal toxicity, mucositis, and diarrhea. 41 Furthermore, the treatment of germ-free (GF) mice (lacking any detectable bacteria) with an anthracycline chemotherapeutic demonstrates the necessity of enteric bacteria in chemotherapy-induced reductions in the depth and number of intestinal crypts, which are structures important for the maintenance and renewal of epithelial cells in the intestine. 42 This field would benefit from further research characterizing the effects of chemotherapeutic drugs on the intestinal microbiota and determining how chemotherapy-associated microbial changes alter the structure and function of the intestines and the CNS.
THE GUT-BRAIN AXIS INFLUENCES BEHAVIOR The Gut-Brain Axis Influences Behavior in Rodents
The intestinal microbiome modulates rodent brain development and function throughout all stages of life. 2 Although hypothesized mechanisms have not yet been adequately delineated, mounting evidence demonstrates associations between the intestinal microbiome and mood and cognition and, to a lesser extent, fatigue and sleep disruptions. 2 For example, GF mice and adult mice that were treated aggressively with antibiotics (eliminating much of the intestinal microbiota) display increases in anxiolytic-like exploratory behaviors (using open-field, elevated plus maze, and light-dark box tests) and impairments in memory in a novel object-recognition test. 43, 44 Furthermore, such manipulations of the gut microbiota modulate neurophysiological changes in the brain regions that regulate these behaviors. For example, mice lacking intestinal microbiota display increased neurogenesis and impaired microglia maturation and activation in response to systemic immune challenges (lipopolysaccharide treatment). 45, 46 Although conflicting trends in some behavioral changes are observed in GF and antibiotic-treated rodents compared with chemotherapy models, taken together, these lines of research support the notion that various alterations in the intestinal microbiome can affect these behaviors and neurophysiological mechanisms. Basic science studies investigating the ability of chemotherapy-induced alterations in the intestinal microbiome to influence behavior and neurophysiology are warranted.
The Gut-Brain Axis Influences Behavior in Humans
Alterations in microbial communities also are associated with affective disorders in humans. [47] [48] [49] For example, fecal bacterial communities from patients with major depressive disorder (MDD) are distinct from those in healthy individuals, and patients with MDD have an increased relative abundance of Actinobacteria and decreased Bacteroidetes. 48 Furthermore, the severity of depressive symptoms is negatively correlated with the abundance of butyrate-producing Faecalibacterium spp. 49 In parallel, the use of probiotics (defined as live microorganisms that, when received in adequate amounts, confer a health benefit on the host) is associated with decreased depressive symptoms in healthy adults as well as patients diagnosed with MDD. 50, 51 Outside of affective disorders, a role for the intestinal microbiome in cognition and fatigue in humans is still being established; therefore, evidence is limited. Patients who are diagnosed with disorders associated with large shifts in intestinal and fecal microbial taxa and systemic inflammation, such as irritable bowel syndrome and cirrhosis, report measurable differences in cognition. 52, 53 For example, increases in fecal Alcaligenaceae and Porphyromonadaceae families are correlated with poor cognitive performance in patients with cirrhosis. 53 Altered fecal microbiomes also are identified in patients who are diagnosed with chronic fatigue syndrome (CFS). [54] [55] [56] In one study, fecal Faecalibacterium was positively correlated with emotional well being scores in patients who were diagnosed with CFS. 55 In another study, antibiotic treatment that successfully reduces fecal Streptococcus abundance in patients with CFS is associated with improved sleep and increased vigor. 56 Additional clinical studies characterizing the intestinal microbiome in patient populations characterized by fatigue and cognitive impairments, such as those with cancer and cancer survivors who previously received chemotherapy, are necessary to strengthen the connection between the intestinal microbiome and these behaviors in humans.
THE GUT-IMMUNE-BRAIN AXIS
The intestinal microbiome is capable of altering brain function simultaneously through multiple pathways, 2 which is likely the case during chemotherapy. The mechanisms by which endocrine and neural pathways mediate signals from the GI tract have been thoroughly reviewed elsewhere. 2 For the current review, we hypothesized that the most relevant pathway between the GI tract and the brain during chemotherapy is the peripheral immune system. This hypothesis is represented in Figure 1 .
Immune Pathways From the GI Tract
It has long been recognized that the intestinal microbiota plays a crucial role in the development and maintenance of the immune system. 57 GF mice exhibit an overall underdeveloped immune system, which can be rescued by conventional microbial colonization from healthy mouse donors. 58 However, recolonization with only select species fails to fully recuperate these deficits, suggesting that normal immune function is the culmination of complex activities of the commensal microbiota as a whole. 58 The intestinal microbiota can influence circulating immunity positively and negatively through direct production of multiple products within the intestinal lumen, influencing infiltration of peripheral immune cells in the intestine. For example, butyrate is a short-chain fatty acid product of microbial fermentation, which is intimately related to intestinal inflammation and immunomodulation through its ability to reduce proinflammatory cytokines. 59 Clinically, decreased luminal concentrations of butyrate and butyrate-producing microbes have been implicated in the development of inflammatory bowel disease. 60, 61 Butyrate therapy has been investigated for the amelioration of a variety of systemic inflammatory processes, including the reduction of chemotherapy-induced mucositis. 62 Furthermore, butyrate and other short-chain fatty acids can promote the migration of leukocytes, although much of this work has been conducted in vitro. 63, 64 It should be noted that these anti-inflammatory actions of butyrate may be physiologically isolated to the intestine, because butyrate concentrations are drastically reduced beyond the portal vein, 65 although this may differ during illness. Relevant to chemotherapy, enteric infections (and resultant inflammation and reduction in barrier function) can increase butyrate concentrations in the circulation. 66 Chemotherapy causes intestinal mucositis and alterations in GI microbial communities, both of which can result in systemic inflammation, as discussed above. For example, chemotherapy-induced diarrhea in cancer patients is associated with increased concentrations of matrix metalloproteinases and nuclear factor jB (NFjB), IL-1b, and TNFa in the circulation. 31 The microbiota has been implicated in the pathogenesis of mucositis Review Article during chemotherapy through its ability to regulate local inflammation and by decreasing intestinal barrier function. 28, 41 In fact, bacteria that have translocated out of the intestine are commonly identified in the circulation of patients with cancer after chemotherapy. 67 Commensal and probiotic Lactobacillus species are broadly investigated for their immunomodulatory potential, and native species are consistently reduced by chemotherapy treatment. 68 Of these species, Lactobacillus reuteri strains (a commensal human species) in particular reduce inflammation through the production of histamine and indole-3-aldehyde. 69 
Inflammation and Behavior
Basic science research indicates that peripheral inflammation can be transduced into neuroinflammation through both neural and humoral pathways. 70 Neuroinflammation induces a wide range of neurophysiological processes involved in mood regulation, cognition, fatigue, and sleep. 71 The neurophysiologic cascades triggered by neuroinflammation (eg, apoptosis) are similarly altered after chemotherapy, 18, 19, 23, 72 and neuroinflammation is regarded as one of the primary mechanisms underlying chemotherapy-associated behavioral comorbidities. 73 Direct evidence supporting a role for neuroinflammation in behavioral disorders in humans stems from brain necropsies from successful suicides by patients with MDD, which are characterized by increased cytokine expression as well as increased microglial activation in brain regions associated with mood regulation and cognition. 74, 75 Indeed, elevated cytokines and cytokine-based treatments in humans have been linked to the development of behavioral disorders. 76, 77 For example, patients with cancer who received interferon a (IFN-a) and IL-2 develop symptoms of depression and anxiety, cognitive dysfunction, and fatigue. 78, 79 Furthermore, the development of depression, anxiety, and impaired memory after low-dose endotoxin treatment is correlated with increases in circulating TNFa expression. 80 Several studies have demonstrated the ability of chemotherapeutic drugs (particularly taxanes) to stimulate immune function 81 and increase circulating expression of inflammatory cytokines in patients with cancer. [82] [83] [84] Furthermore, behavioral comorbidities in patients with Figure 1 . The gut-immune-brain axis is illustrated after chemotherapy. Chemotherapy alters the composition of the intestinal microbial structure, reducing a diversity and species associated with anti-inflammatory activities while increasing intestinal inflammation and permeability. Simultaneously, chemotherapy results in increased peripheral inflammation, neuroinflammation, and impaired central nervous system (CNS) function. Alteration of the intestinal microbial community may result in and exacerbate neuroinflammation and behavioral comorbidities after chemotherapy. Although the brain and the gut can communicate bidirectionally through multiple pathways, including through neuroendocrine pathways and the autonomic nervous system, we hypothesize that, in the context of chemotherapy, the peripheral immune system is the most relevant mediator between the gut and the brain. IL-6 indicates interleukin 6; IL-1b, interleukin 1b; TNFa, tumor necrosis factor a.
cancer and cancer survivors are correlated with these increases in peripheral inflammation. 12, [85] [86] [87] For example, cognitive impairments in breast cancer survivors are associated with increased peripheral inflammatory markers, such as IL-6 and TNFa. 86, 87 Likewise, persistent fatigue in breast cancer survivors is accompanied by increased expression of IL-6 8,88,89 as well as altered gene expression in leukocytes, suggesting enhanced proinflammatory NFjB signaling and decreased anti-inflammatory glucocorticoid signaling. 90 Finally, the use of pharmaceutical and mindfulness-based interventions that inhibit or reduce inflammation have been successful in reducing cancer/ chemotherapy-associated symptoms of fatigue and depression.
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The Gut-Immune-Brain Axis
The intestinal microbiota may increase neuroinflammation and affective behaviors during disease or in response to disease treatments by activating a peripheral immune response. However, few studies have thoroughly investigated the connection between the intestinal microbiota, immune, and brain systems to date; and much of the current data rely on correlational observations. Outside of the cancer context, increased neuroinflammation and altered behavior are concurrent with shifts in intestinal microbiota, intestinal inflammation, and systemic inflammation in mouse models of obesity and colitis. 96, 97 Similarly, probiotic treatment with L. rhamnosus simultaneously ameliorates behavioral changes and reduces systemic inflammation in a model of chronic social stress. 98 Finally, the inhibitory effects of antibiotics on neurogenesis in rodents is mediated by circulating monocytes that express high levels of lymphocyte antigen 6 complex. 45 However, additional experiments elucidating causal mechanisms underlying the gut-immune-brain axis are warranted.
Within the context of cancer, chemotherapy is associated with increased peripheral and central inflammation, behavioral and cognitive disorders, as well as shifts in fecal bacterial diversity and community structure. Although a role for the gut-immune-brain axis has been implicated in chemotherapy-induced pain in mice, 99 the extent to which changes in affective disorders, cognition, and fatigue are influenced by chemotherapy-associated alterations in fecal bacterial community structure remains undetermined. Larger clinical studies characterizing shifts in microbial compositional, metagenomics, and metabolomic profiles after chemotherapy and investigating how these alterations correlate with altered peripheral inflammation and changes in neuroimaging and/or behavior are warranted. In addition, rodent models treated systematically with specific chemotherapy drugs or combinations of drugs to determine mechanistically how changes to the intestinal microbiome and intestinal integrity contribute to peripheral and central inflammation and affect behavior would expand our understanding of the gut-immunebrain axis during disease.
POTENTIAL INTERVENTIONS
Understanding how and the extent to which chemotherapy-induced alterations in the GI microbiome contribute to behavioral comorbidities could transform the manner in which we treat the debilitating side effects experienced by patients with cancer. Specifically, innovative treatment of GI illness using probiotics, prebiotics (defined as nondigestible ingredients that support beneficial bacterial growth), and/or fecal microbiota transplantation (FMT) may reduce behavioral comorbidities, the risk of peripheral infections, and GI symptoms simultaneously, all of which currently interrupt cancer treatment and reduce quality of life.
For example, pairing chemotherapy treatment with probiotic supplementation is a promising co-therapy that reduces GI symptoms, intestinal inflammation, intestinal permeability, and the risk of infection while concurrently increasing bacterial diversity in patients with cancer. [100] [101] [102] Supplementation of probiotics (particularly specific Lactobacillus spp.) is relatively well-investigated for amelioration of behavioral, microbial, and inflammatory morbidities in other patient populations, as discussed throughout this review. Although implementing probiotic interventions to ameliorate psychiatric disorders is a relatively novel approach, most available clinical trials report reduced symptoms of depression and anxiety. 50, 103 For example, consumption of a mixture of L. casei, L. acidophilus, and Bifidobacterium bifidum by patients with MDD reduces symptoms of depression. 51 This same mixture of probiotics also increases cognitive function in patients diagnosed with Alzheimer disease. 104 Similarly, the vast majority of clinical studies focused on probiotic use specifically in patients with cancer are limited to GI-related outcomes. Only one study demonstrated the ability of L. rhamnosus and L. acidophilus treatment to reduce symptoms of depression, anxiety, and fatigue (notably in tandem with reduced GI symptoms) in chemotherapy-treated colorectal cancer survivors, indicating that additional studies are needed to determine the efficacy of these treatments on behavioral comorbidities in patients with cancer. 105 Current clinical trials involving probiotics are further limited by small Review Article sample sizes and differing combinations of probiotic strains and dosages implemented, making meaningful comparisons among studies difficult.
Prebiotic supplementation is less studied compared with probiotics but is also an emerging intestinal microbiota-targeted therapy for attenuating behavioral disorders. This is exemplified by a small number of rodent and human studies. Prebiotic supplementation of rat diets with galactooligosaccharides, polydextrose, and bioactive milk fractions improve sleep quality. 106 In addition, galactooligosaccharides and fructooligosaccharides have a neurotrophic effect, increasing the expression of brainderived neurotrophic factor and N-methyl-D-aspartic acid subunits while concurrently increasing levels of fecal L. rhamnosus colony-forming units and bacterial adiversity in rodents. 106, 107 In healthy humans, consumption of galactooligosaccharides alters neuroendocrine responses and emotional processing, 108 indicating that prebiotics may be a relevant GI-focused treatment for fatigue and mood comorbidities associated with chemotherapy. Beyond supplementation with prebiotics or probiotics, a more general alteration in diet (particularly in terms of fiber and macronutrient composition) rapidly affects the composition of the intestinal microbiome 109 and thus might influence behavior.
Although the health benefits of some microbial therapies are localized to the intestine or immune system, limited numbers of probiotics (eg, B. infantis and L. rhamnosus) and prebiotics (eg, galactooligosaccharides) potentially alleviate symptoms of psychiatric illness. 110 These novel probiotics, which have been termed psychobiotics, represent an emerging subset of probiotics that require further investigation, especially in human populations.
FMT is an additional potential treatment for behavioral comorbidities. Clinical FMT from healthy individuals to patients with Clostridium difficile infection is exceptionally successful in restoring a diverse intestinal microbiota and alleviating devastating GI symptoms. 111 In mice, FMT drastically modifies the resident intestinal microbial composition and also transfers behavioral attributes of the fecal donor. 96, 112 For example, FMT from obese mice to lean mice transfers both the obese intestinal microbial profile (eg, low Akkermansia muciniphila) and the associated cognitive deficits to the lean recipients. 96 To the best of our knowledge, only a single study has examined the safety and efficacy of FMT in patients with cancer after chemotherapy. 113 However, although that study reported success in treating C. difficile infections, the extent to which treatment altered peripheral inflammation and behavior was not reported.
Although FMT is a potential new strategy for ameliorating behavioral comorbidities after chemotherapy, FMT in humans does not always succeed in altering fecal microbiota composition or in conveying the intended benefit (eg, resolving C. difficile infections). 114 Further research using preclinical animal models to increase safety and efficacy will be required before this technique should be applied to cancer populations.
CONCLUSION
Chemotherapy remains one of the harshest but most common systemic clinical treatments for cancer. Therefore, the development of new and innovative treatment strategies to alleviate the associated behavioral and GI comorbidities is essential. The extent to which GI dysfunction influences behavior in chemotherapy-treated patients has yet to be elucidated. However, the ability of the intestinal microbiota to modify immune activity, behavior, and its underlying neurophysiological processes suggests a potential role for the gut-immune-brain axis in chemotherapyassociated comorbidities. Indeed, supporting evidence from both clinical and animal chemotherapy studies demonstrates significant alterations to the composition of intestinal microbiota, increased intestinal inflammation, and reduced GI barrier function. Often, measures of peripheral inflammation are correlated with behavioral deficits in chemotherapy-treated patients with cancer and cancer survivors. Much needed prospective, longitudinal clinical studies in chemotherapy-treated patients would inform basic science work to identify the mechanisms underlying communication between the intestinal microbiome and the brain during specific cancer treatments and the extent to which this communication is mediated by the peripheral immune system. In addition, clinical and preclinical testing of innovative and noninvasive interventions targeting the intestinal microbiota and/or their byproducts is warranted. This work has the potential to improve the health and quality of life of millions of cancer survivors by reducing the prevalence of chemotherapyassociated behavioral comorbidities. 
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